International Stem Cell Corp. continues its pursuit of
advancing regenerative medicine through its use and research of stem cells in
the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell
technology that makes use of unfertilized eggs to address immune system
rejection. The eggs being used have mirroring sets of human leukocyte antigen
genes (HLA) that reduce the chance of immune system rejection. Not to be
overlooked, it’s worth noting that one line of these cells can treat multiple
millions of people. The company can draw human parthenogenetic neural stem
cells (hpNSC) from the unfertilized eggs for self-renewing processes that are
integral to the degeneration process.
Following continuous successful testing, International Stem
Cell Corp. suggests that their human parthenogenetic neural stem cells can take
the place of dead and dying neurons while also protecting existing ones when
transplanted into the brain of someone with Parkinson’s disease. Further,
company researchers and scientists are progressing toward developing human
retinal epithelium (RPE) cells that are used in the treatment of eye diseases
like age-related macular degeneration. Along with that research, the company is
one of the world’s select few to develop a method for creating corneal tissue
and cells to treat blindness.
International Stem Cell has recently announced its
development of technology that creates functional cartilage from a person’s
skin to treat a joint disease that erodes cartilage infamously known as
osteoarthritis. The company is also making strides aside from therapeutic
systems that, according to Chief Scientific Officer, Ruslan Semechkin, PhD,
“can potentially be treated with the patient’s own cells.”
Running concurrent with its work in the area of regenerative
techniques, International Stem Cell Corp. runs a cosmeceutical line called
Lifeline Skin Care Inc. This business makes cosmetic skin care products all
over the globe. The company’s research and development in this area uses
parthenogenetic stem cells, vitamins and minerals to create a rejuvenating
serum leading to healthier skin.
International Stem Cell Corp. works on therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. The company’s
primary technology of parthenogenesis nets the creation of pluripotent human
stem cells from unfertilized oocytes. Company scientists have created the first
parthenogenetic, homozygous stem cell line that is considered by many to be a
source of therapeutic cells for hundreds of millions of individuals of
differing genders, racial background and ages.
For more information about the company, visit
www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
